Ovarian Cancer

>

Latest News

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.
Early Palliative Care May Increase QOL in Ovarian Cancer Decedents Near EOL

November 4th 2024

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.
Rolling NDA Completed for Avutometinib Combo in Ovarian Cancer Subtype

November 1st 2024

Avutometinib Combo Yields Responses in Low-Grade Serous Ovarian Cancer | Image Credit: © Lars Neumann - stock.adobe.com.
Avutometinib Combo Yields Responses in Low-Grade Serous Ovarian Cancer

October 18th 2024

Combining IMNN-001 with chemotherapy also elicited a progression-free survival improvement compared with chemotherapy alone in the OVATION 2 trial.
IMNN-001/Chemo Improves Survival in Advanced Ovarian Cancer

July 31st 2024

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.
FDA Approves Novel Formulation for Breast and Ovarian Cancers

June 28th 2024

Latest CME Events & Activities

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...

November 16, 2024

Register Now!

Community Practice Connections™: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Community Practice Connections™: Optimize the Diagnosis and Treatment of HER2-Positive Colorectal Cancer

View More

Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease

View More

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

Register Now!

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

View More

Towards Personalized Treatment Approaches in Soft Tissue Sarcomas

View More

22nd Annual Winter Lung Cancer Conference®

January 31, 2025 - February 2, 2025

Register Now!

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

Register Now!

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

Exploring the Benefits and Risks of AI in Oncology

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More